LA JOLLA, Calif.--(BUSINESS WIRE)--Nativis Inc., a life science company based in La Jolla, Calif., will unveil its ground-breaking technology to treat diseases in new ways on the television premiere of The Eco Capitalist airing on CNBC World at 7 p.m. (EDT) on Saturday, May 15.
“Green Gold Rush (California)”, The Eco Capitalist takes a close look at some of California’s most forward-thinking companies and how they are ushering in a new era of “Eco-Capitalism.”
One of the companies featured is Nativis.
For the past eight years, Nativis has been developing drug signal therapy, a platform technology based on the pioneering work of several Nobel laureates. A drug signal is a recording of the photon field that surrounds the solvation shell of a molecule in solution. Nativis has developed the technology to capture the unique photon fields (or drug signals) of active pharmaceutical ingredients (API), or drugs, at the atomic level. It then uses its patented technology to deliver the signal in a solution to treat serious diseases in new, safe and more effective ways. Drug signal therapy promises to transform the treatment of diseases, including those for which there are no known cures, like brain cancer.
The drug signal provides the therapeutic equivalent of the “chemical” drug while overcoming the physical hurdles that have limited the effectiveness of traditionally administered molecules. The new technology also has the promise of replacing the current process of producing drug compounds in traditional manufacturing plants, which would reduce the environmental footprint by eliminating waste and conserving energy. The new technology epitomizes the concept for green chemistry, making Nativis the first truly green pharmaceutical company in the world.
"Green chemistry and manufacturing practices hold the promise of contributing to economic growth with less environmental impact," said John Butters, president and CEO of Nativis. “The Eco Capitalist is a great forum to highlight the many advances being made in this sector. It may also stimulate new ideas for how science and technology can be applied to deal with our most challenging issues.”
“We are at the dawn of a new era where the potential for economic opportunity intersects with sustainable and environmentally responsible business practices. Nativis has the potential to significantly impact the green pharmaceutical space and, as such, was an ideal company to showcase on our premier,” said Andrew McLean, host and executive producer.
Drug Signal Therapy
Nativis uses its drug signal therapy to overcome the physical hurdles that have limited the effectiveness of traditionally administered drugs. Many drugs in wide use for treating cancer are unable to successfully treat brain tumors because they are incapable of permeating the blood-brain barrier. The blood-brain barrier, a physiological separation of circulating blood and spinal fluid, successfully protects the brain from common infections but it also hinders the delivery of diagnostics and therapeutic agents. Early preclinical trials have shown that Nativis’ technology can safely pass the blood-brain barrier.
How it works?
The patented technology captures the unique “photon field” of active pharmaceutical ingredients (API) or drugs. Every drug molecule in a solution contains information specific and unique to the molecule. Similar to a measurement of energy, only exquisitely more sensitive, Nativis’ technology captures the photon field surrounding the solvation shell of a molecule in solution.
The Birth of Digitax™
The first application of Nativis’ drug signal technology is DigitaxTM, used to target glioblastoma brain tumors, one of the most aggressive and difficult cancers to treat. Digitax is a taxane-based drug signal captured from the cancer-fighting chemical drug Taxol®. The Digitax drug signal provides the therapeutic equivalent of Taxol. Digitax, delivered orally in a water-based solution, is effective in safely crossing the blood-brain and other barriers and has been proven to reduce and eliminate tumor growth in preclinical studies.
The use of drug signal therapy may also have significant advantages for the patient’s quality of life during treatment; no longer will the patient’s body have to endure toxic chemicals in order to fight the disease because drug signal therapy does not have the same harmful side effects inherent to many chemical drug compounds. To date, Digitax is shown to deliver statistically significant results inhibiting tumor growth and preventing metastasis with no measurable adverse side effects.
By delivering drug signals instead of traditional drug molecules, Nativis can also bypass the lengthy processes and high costs associated with developing traditional pharmaceutical drugs in manufacturing facilities, which require extensive use of chemicals and processes.
In typical drug manufacturing, it takes 100 grams of material to deliver 1 gram of medicine. Leading drug manufacturers can require facilities totaling more than 1 million square feet. Nativis will be able to manufacture an equivalent amount of drug signal therapeutics in facilities of less than 50,000 square feet and without the environmental impacts, remediation and requirements associated with traditional pharmaceutical manufacturing. With smaller, cleaner plants, less costly manufacturing and much shorter turn-around time between identifying a drug signal to receiving FDA approval, Nativis has the potential to not only reduce the cost of treating most diseases but to reduce the environmental footprint by eliminating waste and conserving energy.
The premier of The Eco Capitalist” featuring Nativis’ green chemistry technology will air on CNBC World, Saturday, May 15, at 7 p.m. (ET). For more information visit www.theecocapitalist.com.
Nativis, a La Jolla-based life science company, has created a revolutionary platform technology for drug delivery that promises to transform the treatment of diseases, including those for which there are no known cures, like brain cancer. The patented technology -- drug signal therapy captures the unique drug signal of active pharmaceutical ingredients (API), at the atomic level. The drug signal – or photonic signature – mimics the original chemical molecule and can unlock the same biological processes. The drug signal can be delivered orally, intravenously, intraperitoneally and intrathecally while overcoming the physical hurdles that have limited the effectiveness of traditionally administered molecules. The new technology epitomizes the concept for green chemistry and has the promise of replacing the current process of producing drugs in traditional manufacturing plants, which would reduce the environmental footprint. For more information visit: www.Nativis.com.